Control of Blood Pressure Following Carotid Artery Stenting: Is it Baroreceptor Resetting? (P1.3-058)

Objective: We sought to observe the difference in blood pressure in severe hypertensive patients undergoing carotid artery stenting (CAS) upto one year follow-up. Background: Renal artery stenting controls blood pressure in some patients, is well known. However, blood pressure control after CAS has not been well explored. Design/Methods: This was a single-centre, observational study performed in patients undergoing CAS at a Tertiary care centre in India. Of total 720 patients who underwent CAS, 590 (82%) patients were hypertensive. These 590 patients were monitored for one year for the difference in blood pressure and medication requirements. Results: Of 590 patients, majority had blood pressure above 170 mm Hg, requiring 3 to 4 anti-hypertensive drugs. Following CAS 75% of the patients having hypertension got controlled in immediate post-procedure period. Of these, 38% of the patients didn’t require any anti-hypertensives upto 1 year follow-up and the remaining patients required single drug or 2 drugs. Conclusions: We observed a unique finding that patients with severe hypertension requiring 3 to 4 drugs having severe carotid stenosis had blood pressure controlled with minimal or no drugs following CAS upto one year follow-up. The phenomenon behind this is probably the baroreceptor resetting. However, a trial on larger group of patients with longer follow-up will further support this finding. Disclosure: Dr. Pamidimukkala has nothing to disclose. Dr. Rachaputi has nothing to disclose. Dr. Noronha has nothing to disclose. Dr. Chinta has nothing to disclose. Dr. Ravela has nothing to disclose. Dr. Immadisetty has nothing to disclose. Dr. Prasanna has nothing to disclose. Dr. Polavarapu has nothing to disclose. Dr. Byrapaneni has nothing to disclose. Dr. Polavarapu has nothing to disclose. Dr. Freedman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Myolex, Inc. Dr. Freedman has received compensation for serving on the Board of Directors of Myolex, Inc. Dr. Nakuru has nothing to disclose. Dr. Chilukuri has nothing to disclose. Dr. Gali has nothing to disclose. Dr. Polavarapu has nothing to disclose.